Cholesterol Truths, Tests, and Misleading Data
For over 60 years, cholesterol has been labeled public enemy #1. Millions of Americans are told their numbers are “too high” and are handed a lifetime statin prescription without ever being told what cholesterol actually does in the human body—or how flawed standard testing really is.
In this episode of Think Well, Do Well, Dr. Alan Bradford breaks down the real history and biochemistry of cholesterol. We expose the cherry-picked data behind Ancel Keys’ famous Seven Countries Study, the secret sugar industry payoff that framed dietary fat, why your standard lipid panel is running on an outdated math equation (the Friedewald formula), and why your body desperately needs cholesterol for brain health, sex hormones, and cellular signaling.
In this episode, we cover:
The Seven Countries Study & The French Paradox: Why Ancel Keys ignored data from 15 countries to push the low-fat narrative.
Project 226 & The Harvard Sugar Payoff: How the sugar lobby funded research in the 1960s to shift the blame away from sugar onto fat and cholesterol.
The Moving Goalposts: How “normal” cholesterol dropped from 260 mg/dL to under 200 mg/dL—turning healthy adults into patients overnight.
The Friedewald Formula Flaw: Why your standard calculated LDL may be artificially elevated if you are lean and metabolically healthy.
Golf Balls vs. Beach Balls: Why particle size (small dense vs. large buoyant LDL) and oxidation matter far more than your total number.
The Real Villain (Sugar → Triglycerides): How excess glucose and fructose drive fatty liver and metabolic dysfunction.
Why You Need Cholesterol: The essential raw material for Vitamin D synthesis, testosterone/estrogen production, brain function, and cellular “lipid rafts.”
Actionable Takeaway: How to calculate your own Triglyceride-to-HDL ratio at home to evaluate your real metabolic risk.
References
1. Historical Research & Industry Influence
The Sugar Industry & Harvard Payoff (Project 226):
Kearns, C. E., Schmidt, L. A., & Glantz, S. A. (2016). Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Internal Medicine, 176(11), 1680–1685.
2. Clinical Statin Efficacy & Absolute vs. Relative Risk
Systematic Review on LDL Reduction vs. Real Clinical Endpoints (Byrne & Demasi):
Byrne, P., Demasi, M., et al. (2022). Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Internal Medicine, 182(5), 474–481.
Link: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790055
Statin Impact on Average Survival in Primary Prevention:
Kristensen, M. L., et al. (2015). The effect of statins on average survival in randomised trials, an analysis of investigative data. BMJ Open, 5(9), e007730.
Link: https://bmjopen.bmj.com/content/bmjopen/5/9/e007118.full.pdf
Clinical Commentary on Widespread Statin Use & Immune Vulnerability:
Huber, C. (2024). Statin drugs laid the groundwork. Substack.
Link: https://colleenhuber.substack.com/p/statin-drugs-laid-the-groundwork
3. Laboratory Calculations & LDL Estimation
The Original Friedewald Calculation (1972):
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18(6), 499–502.
The Modern Martin-Hopkins Dynamic Method (2013):
Martin, S. S., et al. (2013). Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA, 310(19), 2061–2068.
Link: https://jamanetwork.com/journals/jama/fullarticle/1779534
Extended Martin-Hopkins Method for Hypertriglyceridemia (2021):
Sajja, A., et al. (2021). Extended Martin/Hopkins calculation for estimating low-density lipoprotein cholesterol in patients with hypertriglyceridemia. JAMA Network Open, 4(10), e2128817.
Link: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785570
4. Cellular Biology, Lipid Rafts & Insulin Signaling
Insulin Receptor Function in Lipid Rafts:
Vainio, S., et al. (2002). Dynamic association of human insulin receptor with lipid rafts in liver-derived cells. The EMBO Journal, 21(11), 2636–2645.
Lipid Rafts, Microdomains, and Insulin Resistance:
Hanzal-Bayer, M., & Hancock, J. F. (2005). Lipid Microdomains and Insulin Resistance: Is There a Connection? Science STKE, 2005(268), pe3.
General Membrane Physiology & Signal Transduction:
Simons, K., & Toomre, D. (2000). Lipid rafts and signal transduction. Nature Reviews Molecular Cell Biology, 1(1), 31–39.
5. Brain Health, Cognition & Neurological Disease
Serum Cholesterol & Cognitive Performance (Framingham Heart Study):
Elias, P. K., et al. (2005). Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosomatic Medicine, 67(1), 24–30.
Low LDL Cholesterol and Parkinson’s Disease Risk:
Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May 15;23(7):1013-1018. doi: 10.1002/mds.22013. PMID: 18381649.
6. Recommended Books Mentioned
Bowden, J., & Sinatra, S. (2012 / Updated 2020). The Great Cholesterol Myth: Why Decreasing Cholesterol Won’t Prevent Heart Disease—and the Statin-Free Plan That Will. Fair Winds Press.
